Brokerages Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $251.70

BeiGene, Ltd. (NASDAQ:BGNE) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $251.70.

A number of research firms have issued reports on BGNE. Guggenheim cut their price target on BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Sanford C. Bernstein cut their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research note on Wednesday, March 27th. JPMorgan Chase & Co. lifted their price target on BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a research note on Tuesday, March 19th. Finally, Bank of America cut their price target on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research note on Monday, April 8th.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 26,716 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total value of $3,977,745.24. Following the transaction, the chief executive officer now owns 12,084 shares in the company, valued at approximately $1,799,186.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total value of $3,977,745.24. Following the transaction, the chief executive officer now owns 12,084 shares in the company, valued at $1,799,186.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The disclosure for this sale can be found here. Insiders have sold 64,781 shares of company stock worth $10,222,381 in the last 90 days. Insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On BeiGene

Several institutional investors have recently bought and sold shares of the company. Knights of Columbus Asset Advisors LLC raised its holdings in BeiGene by 20.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock valued at $80,000 after acquiring an additional 76 shares during the period. Vanguard Personalized Indexing Management LLC raised its holdings in BeiGene by 4.8% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 1,704 shares of the company’s stock valued at $306,000 after acquiring an additional 78 shares during the period. NewEdge Wealth LLC raised its holdings in BeiGene by 7.5% during the 4th quarter. NewEdge Wealth LLC now owns 1,612 shares of the company’s stock valued at $291,000 after acquiring an additional 112 shares during the period. Vestmark Advisory Solutions Inc. raised its holdings in BeiGene by 9.5% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 1,601 shares of the company’s stock valued at $289,000 after acquiring an additional 139 shares during the period. Finally, Parkwood LLC raised its holdings in BeiGene by 3.0% during the 4th quarter. Parkwood LLC now owns 6,464 shares of the company’s stock valued at $1,166,000 after acquiring an additional 191 shares during the period. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Stock Performance

Shares of BeiGene stock opened at $138.99 on Friday. BeiGene has a one year low of $126.97 and a one year high of $266.67. The firm has a market capitalization of $13.29 billion, a price-to-earnings ratio of -16.35 and a beta of 0.61. The business has a 50-day simple moving average of $154.71 and a 200 day simple moving average of $167.69. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.32 and a quick ratio of 2.09.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.08. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The business had revenue of $634.40 million during the quarter, compared to analyst estimates of $632.52 million. During the same period in the previous year, the company posted ($4.29) EPS. The firm’s revenue was up 66.9% compared to the same quarter last year. On average, research analysts anticipate that BeiGene will post -8.87 earnings per share for the current fiscal year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.